Innovus Pharmaceuticals 10-K 1 Apr 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Apr. 01, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	INNOVUS PHARMACEUTICALS, INC.
Entity Central Index Key	0001411879
Trading Symbol	innv
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		2,355,737
Entity Public Float			$ 16.3
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Assets:
Cash	$ 1,248	$ 1,565
Accounts receivable, net	282	68
Prepaid expense and other current assets	1,116	363
Inventories	2,370	1,726
Total current assets	5,016	3,722
Property and equipment, net	247	62
Deposits	21	21
Goodwill	953	953
Intangible assets, net	3,890	4,273
Total assets	10,127	9,031
Liabilities:
Accounts payable and accrued expense	2,622	2,607
Accrued compensation	1,252	1,118
Deferred revenue and customer deposits	108	25
Accrued interest payable	32	4
Derivative liabilities – warrants		59
Contingent consideration		29
Short-term loans payable	266	65
Current portion of notes payable, net of debt discount of $1,008 and $437, respectively	3,073	1,239
Total current liabilities	7,353	5,146
Deferred rent	181
Accrued compensation – less current portion	1,228	1,532
Contingent consideration – less current portion	1,256	1,450
Total non-current liabilities	2,665	2,982
Total liabilities	10,018	8,128
Commitments and contingencies
Stockholders’ equity:
Preferred stock: 7,500,000 shares authorized, at $0.001 par value, no shares issued and outstanding at December 31, 2018 and 2017, respectively
Common stock: 292,500,000 shares authorized, at $0.001 par value, 2,101,284 and 1,594,787 shares issued and outstanding at December 31, 2018 and 2017, respectively	2	2
Additional paid-in capital	43,967	36,541
Accumulated deficit	(43,860)	(35,640)
Total stockholders' equity	109	903
Total liabilities and stockholders’ equity	$ 10,127	$ 9,031

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Notes payable, discount, current	$ 1,008	$ 437
Preferred stock, shares authorized (in shares)	7,500,000	7,500,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, shares authorized (in shares)	292,500,000	292,500,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares issued (in shares)	2,101,284	1,594,787
Common stock, shares outstanding (in shares)	2,101,284	1,594,787

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net revenue:
Net revenue	$ 23,990	$ 8,816
Cost of product sales	4,325	1,848
Operating expense:
Research and development	160	39
Sales and marketing	17,206	6,853
General and administrative	7,991	5,175
Total operating expense	25,357	12,067
Loss from operations	(5,692)	(5,099)
Other income (expense):
Interest expense	(1,446)	(872)
Loss on extinguishment of debt	(1,332)	(700)
Other income (expense), net	(13)	(7)
Fair value adjustment for contingent consideration	204	194
Change in fair value of derivative liabilities		(17)
Total other expense, net	(2,587)	(1,402)
Loss before provision for income taxes	(8,279)	(6,501)
Provision for income taxes		3
Net loss	$ (8,279)	$ (6,504)
Net loss per share of common stock – basic and diluted (in dollars per share)	$ (4.16)	$ (4.32)
Weighted average number of shares of common stock outstanding – basic and diluted (in shares)	1,989,134	1,504,135
Product [Member]
Net revenue:
Net revenue	$ 22,879	$ 8,806
License [Member]
Net revenue:
Net revenue	9	10
Service [Member]
Net revenue:
Net revenue	509
Cooperative Marketing [Member]
Net revenue:
Net revenue	$ 593

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016	1,159,295
Balance at Dec. 31, 2016	$ 1	$ 30,229	$ (29,136)	$ 1,094
Common stock issued for services (in shares)	27,535			1,803
Common stock issued for services		629		$ 629
Stock-based compensation		336		336
Common stock issued upon conversion of convertible debentures and accrued interest (in shares)	122,240
Common stock issued upon conversion of convertible debentures and accrued interest		1,471		$ 1,471
Common stock issued for vested restricted stock units (in shares)	877			26,905
Common stock issued for vested restricted stock units
Relative fair value of shares of common stock issued in connection with notes payable (in shares)	26,905
Relative fair value of shares of common stock issued in connection with notes payable		217		217
Fair value of shares of common stock issued as financing fees in connection with notes payable (in shares)	10,666
Fair value of shares of common stock issued as financing fees in connection with notes payable		99		99
Common stock issued upon exercise of stock options (in shares)	681
Common stock issued upon exercise of stock options		5		5
Sale of common stock and warrants, net of offering costs (in shares)	244,445
Sale of common stock and warrants, net of offering costs	$ 1	3,306		3,307
Reclassification of embedded conversion feature derivative liability upon conversion of convertible debentures		204		204
Common stock issued for the prepayment of royalties due under CRI License Agreement (in shares)	2,143
Common stock issued for the prepayment of royalties due under CRI License Agreement		45		45
Net loss			(6,504)	(6,504)
Reclassification of warrant derivative liability upon adoption of ASU 2017-11
Balances (in shares) at Dec. 31, 2017	1,594,787			1,594,787
Balance at Dec. 31, 2017	$ 2	36,541	(35,640)	$ 903
Common stock issued for services (in shares)	2,603,000			2,602
Common stock issued for services		23		$ 23
Stock-based compensation		470		$ 470
Common stock issued for vested restricted stock units (in shares)	6,797			90,644
Common stock issued for vested restricted stock units
Fair value of shares of common stock issued as financing fees in connection with notes payable (in shares)	23,195
Fair value of shares of common stock issued as financing fees in connection with notes payable		310		310
Sale of common stock and warrants, net of offering costs		2,671		2,671
Net loss			(8,279)	(8,279)
Exercise of warrants, net of offering costs (in shares)	181,200
Common stock issued upon conversion of debt and interest (in shares)	195,186
Common stock issued upon conversion of debt and interest		2,918		2,918
Common stock issued in connection with debt (in shares)	90,644
Common stock issued in connection with debt		959		959
Shares issued in connection with asset purchase (in shares)	6,872
Shares issued in connection with asset purchase		75		75
Reclassification of warrant derivative liability upon adoption of ASU 2017-11			59	$ 59
Balances (in shares) at Dec. 31, 2018	2,101,284			2,101,284
Balance at Dec. 31, 2018	$ 2	$ 43,967	$ (43,860)	$ 109

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (8,279,000)	$ (6,504,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	54,000	12,000
Allowance for doubtful accounts		7,000
Common stock, restricted stock units and stock options issued to employees, board of directors and consultants for compensation and services	491,000	1,136,000
Loss on extinguishment of debt	1,332,000	700,000
Change in fair value of contingent consideration	(204,000)	(194,000)
Change in fair value of derivative liabilities		17,000
Amortization of debt discount	1,369,000	778,000
Amortization of intangible assets	634,000	630,000
Changes in operating assets and liabilities, net of acquisition amounts
Accounts receivable	(213,000)	(42,000)
Prepaid expense and other current assets	(710,000)	112,000
Inventories	(542,000)	(1,126,000)
Deposits		(6,000)
Accounts payable and accrued expense	(207,000)	1,757,000
Accrued compensation	(171,000)	351,000
Deferred rent	181,000
Accrued interest payable	61,000	(3,000)
Deferred revenue and customer deposits	83,000	14,000
Net cash used in operating activities	(6,121,000)	(2,361,000)
Cash flows from investing activities:
Purchase of property and equipment	(238,000)	(45,000)
Acquisitions, net of cash acquired	(237,000)
Payment on contingent consideration	(19,000)	(13,000)
Net cash used in investing activities	(494,000)	(58,000)
Cash flows from financing activities:
Proceeds from short-term loans payable	313,000
Payments on short-term loans payable	(159,000)	(33,000)
Proceeds from notes payable and convertible debentures	5,470,000	1,650,000
Payments on notes payable	(2,181,000)	(426,000)
Proceeds from stock option and warrant exercises	2,853,000	5,000
Issuance of common stock for services	2,000
Proceeds from sale of common stock and warrants, net of offering costs		3,308,000
Payments on convertible debentures		(1,223,000)
Prepayment penalty on extinguishment of convertible debentures		(127,000)
Net cash provided by financing activities	6,298,000	3,154,000
Net change in cash	(317,000)	735,000
Cash at beginning of year	1,565,000	830,000
Cash at end of year	1,248,000	1,565,000
Supplemental disclosures of cash flow information:
Cash paid for income taxes		6,000
Cash paid for interest	5,000	90,000
Supplemental disclosures of non-cash investing and financing activities:
Common stock issued for conversion of convertible debentures, notes payable and accrued interest	1,872,000	1,093,000
Relative fair value of common stock issued in connection with notes payable recorded as debt discount	959,000	217,000
Fair value of common stock issued as financing fees in connection with notes payable recorded as debt discount	310,000	99,000
Offering costs in connection with warrant exercises included in accounts payable and accrued expenses	181,000
Reclassification of warrant derivative liability upon adoption of ASU 2017-11	59,000
Proceeds from short-term loans payable for payment of business insurance premiums	175,000	98,000
Consulted [Member]
Supplemental disclosures of non-cash investing and financing activities:
Fair value of non-forfeitable common stock issued to consultant included in accounts payable and accrued expense		360,000
CRI [Member]
Supplemental disclosures of non-cash investing and financing activities:
Fair value of common stock issued for prepayment of future royalties due under the CRI License Agreement included in prepaid expense and other current assets		45,000
Additional Paid-in Capital [Member]
Cash flows from operating activities:
Net loss
Supplemental disclosures of non-cash investing and financing activities:
Reclassification of the fair value of the embedded conversion features from derivative liability to additional paid-in capital upon conversion		$ 204,000
Reclassification of warrant derivative liability upon adoption of ASU 2017-11

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 1 Organization Innovus Pharmaceuticals, Inc., together with its subsidiaries is a Nevada formed, San Diego, California-based The Company’s business model leverages its ability to (a) develop and build its current pipeline of proprietary products, and (b) to also acquire outright or in-license commercial products that are supported by scientific and/or clinical evidence, place them through the Company’s existing supply chain, retail and on-line (including our Amazon®, eBay®, Wish.com, Walmart.com®, and Walgreens.com on-line stores and other e-commerce business platforms) channels to tap new markets and drive demand for such products and to establish physician relationships. The Company currently sells its products direct to consumer primarily in the United States and Canada and sells to international commercial partners in multiple countries around the world Basis of Presentation and Principles of Consolidation These consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), and include all assets, liabilities, revenues and expenses of the Company and its wholly owned subsidiaries: FasTrack Pharmaceuticals, Inc. ("FasTrak"), Semprae Laboratories, Inc. (“Semprae”), Novalere, Inc. (“Novalere”), Supplement Hunt, Inc. (“Supplement Hunt”) and Prime Savings Club, Inc. (“Prime Savings Club”). All material intercompany transactions and balances have been eliminated. Certain items have been reclassified to conform to the current year presentation. Reverse Stock Split On March 15, 2019, ’ ’ one 105 not “ ” Use of Estimates The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP ” Liquidity The Company’s operations have been financed primarily through proceeds from convertible debentures and notes payable, sales of its common stock and revenue generated from its products domestically and internationally through the Company's marketing platform and by its partners. These funds have provided Innovus with the resources to operate its business, sell and support its products, attract and retain key personnel and add new products to the Company's portfolio. The Company has experienced net losses and negative cash flows from operations each year since its inception. As of December 31, 2018, 43.9 2.3 In January 2019, $2.7 11 2018, 5.5 six $2.9 5, 7 11 As of December 31, 2018, 1.2 0.4 March 29, 2019, $1.7 $0.6 December 31, 2018, $6.1 first 2019 $2.7 11 12 June 30, 2016 $1.2 no may not Fair Value Measurement The Company’s financial instruments are cash, accounts receivable, accounts payable, accrued liabilities, derivative liabilities, contingent consideration and debt. The recorded values of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The fair values of the warrant derivative liabilities and embedded conversion feature derivative liabilities are based upon the Black Scholes Option Pricing Model (“Black-Scholes”) and the Path-Dependent Monte Carlo Simulation Model calculations, respectively, and are a Level 3 8 3 3 The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 3 three ● Level 1 ● Level 2 1 ● Level 3 Cash Cash consists of cash held with financial institutions with original maturities of three may Concentration Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and accounts receivable. Accounts receivable consist primarily of cooperative marketing sales which are managed by a third third s products on e-commerce. The Company performs ongoing credit evaluations of its customers and generally do not Revenues consist primarily of product sales directly to end user customers. The Company has no 10% December 31, 2018 2017. December 31, 2018, 2017 two four 78% 72% The Company categorizes revenue by geographic area based on selling location. All operations are currently located in the U.S. The Company’s U.S. and Canada sales represented 80% 19%, December 31, 2018. none 10% The Company operates on the basis of a single reportable segment, which is the business of delivering over-the-counter medicines, consumer care products for men’s and women’s health and respiratory diseases, and other consumer care goods. The Company's chief operating decision-maker is the Chief Executive Officer, who evaluates us as a single operating segment. Concentration of Suppliers The Company has manufacturing relationships with a number of vendors or manufacturers for its various products. Pursuant to these relationships, the Company purchases products through purchase orders with its manufacturers. Inventories Inventories are stated at the lower of cost or market (net realizable value). Cost is determined on a first first The Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and raw materials on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses. Property and Equipment Property and equipment, including software, are recorded at historical cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets which range from three ten Business Combinations The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The final purchase price may one may not Unanticipated events and circumstances may may Goodwill and Intangible Assets The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicates an impairment may two Step 1. may second no Step 2. Impairment may The goodwill was recorded as part of the acquisition of Semprae that occurred on December 24, 2013, February 5, 2015, March 1, 2016. no no December 31, 2018 2017. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives, which range from one fifteen Long-Lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not no December 31, 2018 2017, not Debt Issuance Costs Debt issuance costs represent costs incurred in connection with the notes payable and convertible debentures during the years ended December 31, 2018 2017. Beneficial Conversion Feature If a conversion feature of convertible debt is not Derivative Liabilities Prior to the adoption of ASU 2017 11, January 2015 not 815. 2017 11 January 1, 2018, no 8 Debt Extinguishment Any gain or loss associated with debt extinguishment is recorded in the consolidated statements of operations in the period in which the debt is considered extinguished. Third party fees incurred in connection with a debt restructuring accounted for as an extinguishment are capitalized. Fees paid to third Income Taxes Income taxes are provided for using the asset and liability method whereby deferred tax assets and liabilities are recognized using current tax rates on the difference between the financial statement carrying amounts and the respective tax basis of the assets and liabilities. The Company provides a valuation allowance on deferred tax assets when it is more likely than not not The Company recognizes the benefit of a tax position only after determining that the relevant tax authority would more likely than not 50% no December 31, 2018 2017 9 Revenue Recognition and Deferred Revenue The Company generates revenue from product sales and the licensing of the rights to market and commercialize our products. Revenue is measured based on consideration specified in a contract with a customer. A contract with a customer exists when the Company enters into an enforceable contract with a customer. The contract is based on either the acceptance of standard terms and conditions on the websites for e-commerce customers and via telephone with our third 30 A performance obligation is a promise in a contract to transfer a distinct product to the customer, which for the Company is transfer of over-the-counter drug and consumer care products to its customers. Performance obligations promised in a contract are identified based on the goods that will be transferred to the carrier who takes control of the product that are both capable of being distinct and are distinct in the context of the contract, whereby the transfer of the goods is separately identifiable from other promises in the contract. The transaction price of a contract is allocated to each distinct performance obligation and recognized as revenue when or as the customer receives the benefit of the performance obligation. The transaction price is determined based on the consideration to which we will be entitled to receive in exchange for transferring goods to the customer. We issue refunds to e-commerce and print media customers, upon request, within 30 90 not $194,000 $53,000 December 31, 2018 December 31, 2017, The Company recognizes revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer when product is shipped. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of product sales. The Company enters into exclusive distributor and license agreements that are within the scope of ASC Topic 606. three 1 2 3 no Cost of Product Sales Cost of product sales includes the cost of inventories, shipping costs, warehouse labor costs, royalties and inventory reserves. The Company is required to make royalty payments based upon the net sales of three October 2017, 2018 Advertising Expense Advertising costs, which primarily includes print and online media advertisements, are expensed as incurred and are included in sales and marketing expense in the accompanying consolidated statements of operations. Advertising costs were approximately $14.1 $5.4 December 31, 2018 2017, Research and Development Costs Research and development (“R&D”) costs, including research performed under contract by third Stock-Based Compensation The Company accounts for stock-based compensation in accordance with FASB ASC 718, Stock Based Compensation 718 No. 2016 09 January 1, 2017, Except for transactions with employees and directors that are within the scope of FASB ASC 718, Equity Instruments Issued to Non-Employees for Services The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows FASB guidance. As such, the value of the applicable stock-based compensation is periodically remeasured, and income or expense is recognized during the vesting terms of the equity instruments. The measurement date for the estimated fair value of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the estimated fair value of the equity instrument is primarily recognized over the term of the consulting agreement. According to FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable equity instruments should not Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding and vested but deferred RSUs during the period presented. Diluted net loss per share is computed using the weighted average number of common shares outstanding and vested but deferred RSUs during the periods plus the effect of dilutive securities outstanding during the periods. For the years ended December 31, 2018 2017, 7 Change in Accounting Principle On January 1, 2018, No. 2017 11, Earnings Per Share (Topic 260 480 815 no no January 1, 2018. January 1, 2018 $59,000 January 1, 2018. not Recent Accounting Pronouncements In February 2016, No. 2016 02, Leases (Topic 842 606, Revenue from Contracts with Customers no 2016 02 December 15, 2018, not may not 2016 02 first 2019 December 31, 2018. December 31, 2018 We elected the standard's package of practical expedients on adoption, which allows us to carry forward our historical assessment of whether existing agreements contain a lease and the classification of our existing lease agreements as either operating or capital (referred to as operating or financing leases in the new standard). We did not not may While the Company is currently assessing the impact ASU 2016 02 10. In January 2017, 2017 04, Intangibles - Goodwill and Other (Topic 350 2 2 December 15, 2019, not In June 2018, 2018 07 December 15, 2018, not In August 2018, 2018 13 3 1 2. December 15, 2019, not In August 2018, 2018 15, Customer s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract December 31, 2020 In November 2018, 2018 18, Clarifying the Interaction Between Topic 808 606 606. December 31, 2020

Note 2 - License Agreements

Note 2 - License Agreements	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 2 In-License Agreements Seipel Group Pty Ltd. In-License Agreement On September 29, 2016, 25,000 12 December 31, 2018. Out-License Agreements Acerus Pharmaceuticals Corporation Agreement On January 5, 2018, ten $1.65 $1.21 December 31, 2018) During 2018, $78,000 $100,000 ten December 31, 2018, $70,000 December 31, 2018, $311,000. December 31, 2018, 509,000 35,000 2019. Lavasta Pharma FZ-LLC Agreement On January 18, 2018, ten During 2018, $25,000 ten December 31, 2018, $23,000 On October 19, 2018, No. 1 $15,000 ten During the year ended December 31, 2018, $156,000 Luminarie Pty Ltd. Agreement On May 16, 2017, ten July 2017 September 2017. December 31, 2018 2017, not Densmore Pharmaceutical International Agreement On April 24, 2017, ten $8,000 December 31, 2017. December 31, 2018 2017, $0 $100,000, July 2017, LI USA Co. Agreement On November 9, 2016, ten $2.0 March 2018. 12 first first March 2017. December 31, 2018 2017, $82,000 $60,000, On October 26, 2017, 2018, not not Sothema Laboratories Agreement On September 23, 2014, $200,000 On July 25, 2018, As the sales-based milestones do not 606, December 31, 2018 2017, not no Orimed Pharma Agreement On September 18, 2014, twenty $100,000 As the sales-based milestones do not 606, December 31, 2018 2017, $98,000 $31,000, no December 31, 2018 2017, $13,000 $4,000,

Note 3 - Business and Asset Acq

Note 3 - Business and Asset Acquisitions	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 3 Acquisition of Supplement Hunt On December 14, 2018 ” 2464573 $221,000. $96,000, $125,000. Acquisition of Novalere in 2015 On February 5, 2015 ( With the Merger, the Company acquired the worldwide rights to market and sell the FlutiCare® brand (fluticasone propionate nasal spray) and the related third 2014 third Due to the delay in approval of the Acquisition Manufacturer’s OTC ANDA by the FDA, in May 2017, third 10 November 2014 may 2019. second Under the terms of the Merger Agreement, at the Closing Date, the Novalere Stockholders received 50% 50% 18 18 In addition, the Novalere Stockholders are entitled to receive, if and when earned, earn-out payments (the “Earn-Out Payments”). For every $5.0 $500,000, $2.5 no May 2017. On November 12, 2016, 121,989 s common stock held by Novalere Holdings until the second 2017. not February 1, 2017, not May 15, 2017, 10% 243,978. 1 February 1, 2017 243,978 1 March 15, 2017. $3.0 1,323 not $7 $9,000 December 31, 2018 2017, December 31, 2018 2017, 1,323 $2,000 $23,000, As of December 31, 2018, not not no $1.2 December 31, 2018 2017.

Note 4 - Assets and Liabilities

Note 4 - Assets and Liabilities	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	NOTE 4 Inventories Inventories consist of the following (dollars in thousands): December 31, 2018 2017 Raw materials and supplies $ 238 $ 165 Work in process 96 153 Finished goods 2,036 1,408 Total $ 2,370 $ 1,726 Property and Equipment Property and equipment consist of the following (dollars in thousands): December 31, 2018 2017 Computer equipment $ 45 $ 22 Office furniture and fixtures 82 34 Leasehold improvements 186 25 Production equipment 285 278 Software 339 339 Total cost 937 698 Less accumulated depreciation (690 ) (636 ) Property and equipment, net $ 247 $ 62 Depreciation expense for the years ended December 31, 2018 2017 54,000 12,000 Intangible Assets Amortizable intangible assets consist of the following (dollars in thousands): December 31, 2018 Accumulated Useful Lives Amount Amortization Net Amount (years) Patent & Trademarks $ 654 $ (161 ) $ 493 7 - 15 Customer Contracts 625 (311 ) 314 10 Sensum+® License (from CRI) 234 (131 ) 103 10 Vesele® Trademark 25 (12 ) 13 8 Beyond Human® Website and Trade Name 222 (112 ) 110 5 - 10 Novalere Manufacturing Contract 4,681 (1,824 ) 2,857 10 Other Beyond Human® Intangible Assets 5 (5 ) - 1 - 3 Total $ 6,446 $ (2,556 ) $ 3,890 December 31, 2017 Accumulated Useful Lives Amount Amortization Net Amount (years) Patent & Trademarks $ 418 $ (125 ) $ 293 7 - 15 Customer Contracts 611 (250 ) 361 10 Sensum+® License (from CRI) 234 (107 ) 127 10 Vesele® Trademark 25 (10 ) 15 8 Beyond Human® Website and Trade Name 222 (72 ) 150 5 - 10 Novalere Manufacturing Contract 4,681 (1,356 ) 3,325 10 Other Beyond Human® Intangible Assets 5 (3 ) 2 1 - 3 Total $ 6,196 $ (1,923 ) $ 4,273 Amortization expense for the years ended December 31, 2018 2017 634,000 630,000 December 31, 2018 2019 $ 706 2020 699 2021 657 2022 614 2023 578 Thereafter 636 Total $ 3,890 Prepaid Expense and Other Current Assets Prepaid expense and other current assets consist of the following (dollars in thousands): December 31, 2018 2017 Prepaid insurance $ 173 $ 110 Prepaid inventory 251 125 Merchant net settlement reserve receivable 445 - Prepaid consulting and other expense 111 83 Prepaid CRI royalties 45 45 Other receivables 91 - Total $ 1,116 $ 363 Accounts Payable and Accrued Expense Accounts payable and accrued expense consist of the following (dollars in thousands): December 31, 2018 2017 Accounts payable $ 1,845 $ 2,306 Accrued credit card balances 215 73 Accrued royalties 25 132 Sales returns and allowances 194 53 Accrual for stock to be issued to consultants 131 43 Accrued other 212 - Total $ 2,622 $ 2,607

Note 5 - Notes Payable and Debe

Note 5 - Notes Payable and Debentures - Non-related Parties	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Long-term Debt [Text Block]	NOTE 5 Short-Term Loan Payable The short-term loan payable consists of the financing of our business insurance premiums with a third $175,000. nine $16,000 six $6,000 December 31, 2018 $108,000. Additionally, the Company has entered into short-term loans with certain merchant processors throughout the year. These loans are repaid using processed sales. The balance outstanding as of December 31, 2018 $157,000 Notes Payable The following table summarizes the outstanding notes payable at December 31, 2018 2017 2018 2017 Notes payable: February 2016 Note Payable $ - $ 55 September 2017 5% Notes Payable - 165 October and December 2017 Notes Payable - 1,066 December 2017 5% Note Payable - 390 January and March 2018 Notes Payable 112 - February and March 5% Notes Payable 250 - July 2018 5% Notes Payable 550 - August 2018 Notes Payable 800 - September 2018 5% Notes Payable 390 - October 2018 5% Notes Payable 550 - November and December 2018 Notes Payable 1,429 - Total notes payable 4,081 1,676 Less: Debt discount (1,008 ) (437 ) Carrying value 3,073 1,239 Less: Current portion (3,073 ) (1,239 ) Notes payable, net of current portion $ - $ - The following table summarizes the future minimum payments as of December 31, 2018 2019 $ 4,081 February 2016 On February 24, 2016, 2014 1 $550,000 20% “February 2016 February 19, 2016 ( February 2016 March 19, 2016 24 $28,000. third February 2016 February 19, 2018. February 2018, February 2016 September 2017 5% On September 20, 2017, third $150,000 5% $15,000 $165,000 5% May 20, 2018. In connection with the note, we issued the investor restricted shares of common stock totaling 8,524 $70,000. In April 2018, September 2017 5% 14,041 $170,000. $196,000. $170,000 $27,000 $12,000 October December 2017 On October 17, 2017, October 20, 2017 December 4, 2017, two third $500,000 October 2017 $500,000 December 2017 0% “October December 2017 $200,000 nine $67,000 July 2018 twelve $50,000 December 2018. October December 2017 no 27% October 20% December. On March 1, 2018, October December 2017 21,429 October December 2017 $167,000. $385,000. $167,000 $218,000 $38,000 On July 31, 2018, October December 2017 22,676 $250,000. $367,000. $250,000 $117,000 $67,000 December 2017 5% On December 13, 2017, third $350,000 5% “December 2017 5% $40,000, 5% $140,000, $133,000 $132,000 June 15, 2018, September 15, 2018 December 15, 2018, On July 23, 2018, December 2017 5% 36,502 $402,000. $682,000. $402,000 $280,000 $43,000 January March 2018 On January 8, 2018, January 30, 2018, March 1, 2018 March 2, 2018, three third $678,000 January 2018 $550,000 March 2018 0% “January March 2018 $269,000 0% $1.5 twelve $68,000 February 2018 January 2019 $56,000 April 2018 March 2019. 22% January March 2018 In connection with the January March 2018 12,210 January March 2018 $227,000 January 2018 $188,000 March 2018. 5,918 January 2018 2,998 March 2018 third $68,000 January 2018 $55,000 March 2018 January March 2018 January March 2018 On July 31, 2018, two January March 2018 27,211 $300,000. $440,000. $300,000 $140,000 $100,000 On November 6, 2018, one January March 2018 11,905 $100,000. $133,000. $100,000 $33,000 $24,000 February March 2018 5% On February 28, 2018 March 28, 2018, two third $650,000 5% “February March 2018 5% $70,000 $720,000 5% October 28, 2018 February 2018 three October 1, 2018, January 1, 2019 April 1, 2019 March 2018. In connection with the February March 2018 5% 14,143 February March 2018 5% $94,000 February 2018 $129,000 March 2018. February March 2018 5% On October 8, 2018, one February March 2018 5% 40,481 $340,000. $485,000. $340,000 $145,000 $3,000 On November 30, 2018, one February March 2018 5% 20,940 $143,000. $231,000. $143,000 $88,000 July 2018 5% On July 19, 2018, third $500,000 5% “July 2018 5% $50,000 $550,000 5% February 19, 2019. In connection with the note, the Company issued the investor restricted shares of common stock totaling 15,239 $226,000. August 2018 On August 1, 2018, two third $1 0% “August 2018 $200,000 twelve $100,000 August 2019. August 2018 no 20% In connection with the August 2018 9,524 August 2018 $435,000. 6,086 third $100,000 August 2018 August 2018 September 2018 5% On September 12, 2018, third $350,000 5% “September 2018 5% $40,000 $390,000 5% three March 12, 2019, June 12, 2019 September 12, 2019 In connection with the September 2018 5% 9,524 September 2018 5% $130,000. October 2018 5% On October 22, 2018, third $500,000 5% “October 2018 5% $50,000 $550,000 5% May 1, 2019. In connection with the October 2018 5% 15,239 October 2018 5% $176,000. November December 2018 On November 6, 2018, November 8, 2018 December 12, 2018, three third $1.25 0% “November December 2018 $270,000 $1.52 0% In connection with the November December 2018 14,763 November December 2018 $374,000 November 2018 $125,000 December 2018. 8,193 third $88,000 November December 2018 November December 2018 Interest Expense The Company recognized interest expense on notes payable of $55,000 $73,000 December 31, 2018 2017, December 2018 2017 $1.4 $348,000,

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 6 Accrued Compensation – Related Party Long-term accrued compensation at December 31, 2018 2017 no July 2016.

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7 Capital Stock We have 292,500,000 $0.001 7,500,000 $0.001. may one 1, March 15, 2019 not Issuances of Common Stock Public Equity Offering On March 21, 2017, $3.85 $3.31 The public offering price per share of common stock sold was $15.75. five one $15.75 one one $15.75 244,445 244,445 244,445 $3.31 $1.59 $1.08 $0.64 In connection with this offering, we issued to H.C. Wainwright & Co. (“HCW”), the underwriter in the offering, a warrant to purchase up to 12,223 $443,000. may $19.688 125% March 21, 2017 March 21, 2022. $130,000 no In connection with this offering, we incurred $99,000 Other Stock Issuances and Related Stock-Based Compensation On October 10, 2017, third 19,048 January 30, 2018. December 31, 2017, 3,175 $29,000 December 31, 2017. On November 17, 2016, third 2,620 May 17, 2017. December 31, 2017, $52,000 On September 1, 2016, third 19,048 July 20, 2017 December 31, 2017. 11,429 November 9, 2017. December 31, 2017, 14,186 $206,000 no December 31, 2018. On August 23, 2016, third 15,239 four August 23, 2017. December 31, 2017, 7,620 $360,000 December 31, 2017, $465,000 In July 2016, 953 $23,000 December 31, 2016. January 2017, 2,143 2017. $45,000 December 31, 2018 not On June 16, 2016, third 2,381 December 16, 2016, June 16, 2017 762 $15,000 January 19, 2017, 752 June 16, 2017. $15,000 December 31, 2017, $28,000 In 2018 2017, 2,602 1,803 $23,000 $19,000 December 31, 2018 2017, In 2018 2017, 90,644 26,905 $1,241,000 $217,000, December 31, 2018 2017. 2018 2017, $1,872,000 $1,093,000 195,186 122,240 December 31, 2018 2017 $2,918,000 $1,324,000, 5 2013 The Company issued common stock, restricted stock units and stock option awards to employees, non-executive directors and outside consultants under the 2013 “2013 February 2013. 2013 95,268 2013 no one three first three ten not December 31, 2018, no 2013 2014 The Company issued common stock, restricted stock units and stock options to employees, non-executive directors and outside consultants under the 2014 “2014 November 2014. 2014 190,477 2014 one three first three ten not December 31, 2018, 86 2014 2016 On March 21, 2016, 2016 October 20, 2016 2016 “2016 2016 November 2016. 2016 190,477 2016 2016 January 1 2016 4% December 31, March 2017, 53,936 2016 2016 2016 one three first three ten not December 31, 2018, 139,911 2016 Stock Options For the years ended December 31, 2018 2017, 2018 2017 Expected life (in years) 7.0 9.1 Expected volatility 188.8 % 213.6 % Average risk-free interest rate 2.67 % 2.30 % Dividend yield 0 % 0 % Grant date fair value $ 14.70 $ 15.75 The dividend yield of zero no 718. The following table summarizes the number of stock options outstanding and the weighted average exercise price: Options Weighted average exercise price Weighted remaining contractual life (years) Aggregate intrinsic value Outstanding at December 31, 2016 2,274 $ 22.67 8.6 $ 14,293 Granted 444 $ 16.19 - - Exercised (684 ) 7.17 - - Cancelled (1,184 ) $ 32.64 - - Forfeited - - - - Outstanding at December 31, 2017 850 $ 17.86 9.0 377 Granted 3,936 13.95 - - Exercised - - - - Cancelled (288 ) 14.93 - - Forfeited - - - - Outstanding at December 31, 2018 4,498 $ 14.63 9.2 $ 190 Vested and Expected to Vest at December 31, 2018 4,498 $ 14.63 9.2 $ 190 Vested and Expected to Vest at December 31, 2017 850 $ 17.86 9.0 $ 377 The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding stock options and the quoted price of our common stock at December 31, 2018 2017. December 31, 2017 2016, $13,000 $7,000, Restricted Stock Units The following table summarizes the restricted stock unit activity for the years ended December 31, 2018 2017: Restricted Stock Units Outstanding at December 31, 2016 122,644 Granted 27,709 Exchanged (877 ) Cancelled (23,810 ) Outstanding at December 31, 2017 125,666 Granted 71,528 Exchanged (6,797 ) Cancelled (14,632 ) Outstanding at December 31, 2018 175,765 Vested at December 31, 2018 107,817 Vested at December 31, 2017 94,044 The vested restricted stock units at December 31, 2018 2017 not not 10 may The Company calculates the fair value of the restricted stock units based upon the quoted market value of the common stock at the date of grant. The grant date fair value of restricted stock units issued during the years ended December 31, 2018 2017 $1.1 $516,000, December 31, 2018 2017, $457,000 $329,000, December 31, 2018, not $823,000 2.1 Warrants Outstanding Warrants In January 2015, 2,381 $31.50 January 2015 January 21, 2020. 2015, $9.408 5,588 In connection with the Q3 2015 17,223 $31.50 2020 9,846 December 31, 2016. 7,377 December 31, 2018. In connection with the 2016 $42.00 2021. 40,201 December 31, 2018. In connection with the public equity offering in March 2017, 244,445 $15.75 244,445 $15.75 2022 2018. December 31, 2018, 180,247 953 March 2018. 12,223 $19.69 2022, March 2018 8,219 $19.69 2023 For the year ended December 31, 2018, not December 31, 2017, 2017 Expected life (in years) 5.0 Expected volatility 183.8 % Average risk-free interest rate 2.69 % Dividend yield 0 % As of Dec 31, 2018, 319,493 December 31, 2018 $19.51 3.1 $0. Net Loss per Share Restricted stock units that are vested but the issuance and delivery of the shares are deferred until the employee or director resigns are included in the basic and diluted net loss per share calculations. The weighted average shares of common stock outstanding used in the basic and diluted net loss per share calculation for the years ended December 31, 2018 2017 1,885,311 1,403,699 The weighted average restricted stock units vested but issuance of the common stock is deferred until there is a change in control, a specified date in the agreement or the employee or director resigns used in the basic and diluted net loss per share calculation for the years ended December 31, 2018 2017 103,823 100,436, The total weighted average shares outstanding used in the basic and diluted net loss per share calculation for the years ended December 31, 2018 2017 1,989,134 1,504,135 The following table shows the anti-dilutive shares excluded from the calculation of basic and diluted net loss per common share as of December 31, 2018 2017: As of December 31, 2018 2017 Gross number of shares excluded: Restricted stock units – unvested 67,948 31,622 Stock options 4,498 850 Warrants 319,493 566,195 Total 391,939 598,667 The above table does not 1,323 December 31, 2018 2017 3

Note 8 - Derivative Liabilities

Note 8 - Derivative Liabilities	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	NOTE 8 Prior to the adoption of ASU 2017 11, January 2015 not 815. 2017 11 January 1, 2018, no The derivative liabilities were a Level 3 3 December 31, 2018 2017 Fair Value Measurements Using Level 3 Warrant derivative liabilities: Beginning balance December 31, 2016 $ 164 Change in fair value (105) Ending balance December 31, 2017 59 Cumulative adjustment from liabilities to accumulated deficit for the fair value of the warrant derivative liability upon adoption of ASU 2017-11 on January 1, 2018 (59) Change in fair value - Ending balance December 31, 2018 $ -

Note 9 - Income Taxes

Note 9 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 9 We are subject to taxation in the United States and California, Colorado and South Carolina. The provision for income taxes for the years ended December 31, 2018 2017 2018 2017 Current: Federal $ - $ - State - 3 Total current - 3 Deferred: Federal 1,347 1,056 State 618 (614 ) Change in valuation allowance (1,965 ) (442 ) Total deferred - - Income tax provision $ - $ 3 At December 31, 2018, $30 $29.3 2018 $24.4 may 2037, 2018 $5.6 80% No December 31, 2018 2017, On December 22, 2017, “ 35% 21% January 1, 2018. December 31, 2017 $3.1 no December 31, 2017 In conjunction with the Act, the SEC staff issued Staff Accounting Bulletin No. 118 “ 118” not December 31, 2018. no December 31, 2018 may may may At December 31, 2018 2017, 2018 2017 Net operating loss carry-forwards $ 8,358 $ 6,730 State taxes 1 1 Equity based instruments 370 324 Deferred compensation 741 813 Intangibles - - Derivative liabilities - - Other 316 191 Total deferred tax assets 9,786 8,059 Intangibles (604 ) (825 ) Derivative liabilities (6 ) (5 ) Warrants - (2 ) Debt discount - (16 ) Other - - Total deferred tax liabilities (610 ) (848 ) Less: valuation allowance (9,176 ) (7,211 ) Net deferred tax assets $ - $ - At December 31, 2018 2017, $9.2 $7.2 December 31, 2018 2017 $2.0 not not Pursuant to Section 382 1986, 50 three one five 50 not We have experienced an ownership change with regard to Semprae operating losses. Out of approximately $19,482,000 December 24, 2013, $44,000 $844,000 We have experienced an ownership change with regard to Novalere operating losses. A study has not A reconciliation of the statutory federal income tax rate for the years ended December 31, 2018 2017 2018 2017 Expected federal tax 21.00 % 34.00 % State tax (net of federal benefit) - % (0.03 )% Contingent consideration - % 0.86 % Fair value of embedded conversion feature in excess of allocated debt proceeds - % - % Loss on extinguishment of debt (2.58 )% (3.52 )% Restricted stock units (0.39 )% (0.18 )% Stock options - % (0.21 )% Change in federal tax rate - % (45.59 )% Release of valuation allowance - % 45.59 % Other (0.67 )% (0.12 )% Valuation allowance (17.36 )% (30.85 )% Total - % (0.05 )% The Company follows FASB ASC 740 10, Uncertainty in Income Taxes not December 31, 2018 2017. not twelve no 2018 2017. three

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 10 Royalties and Other Obligations Acquisition of Novalere in 2015 On November 12, 2016, 121,989 second 2017. not February 1, 2017, not May 15, 2017, 10% 243,978 1 February 1, 2017 243,978 1 March 15, 2017. $3.0 1,323 not $7 $9,000 December 31, 2018 2017, December 31, 2018 2017, 1,323 $2,000 $23,000, As of December 31, 2018, not not Seipel Group Pty Ltd. In-License Agreement On September 29, 2016, 12 December 31, 2018. West-Ward Pharmaceuticals International Limited Agreement In May 2017, 50 No. 207957 November 2017. two one not 90 March 2019. Operating Lease In December 2013, 2,578 December 10, 2013 January 31, 2019. $7,000, 4% August 2017, not November 1, 2017. $15,000, $22,000 December 31, 2017. In October 2017, 16,705 December 1, 2017 April 30, 2023. $21,000 3% January 2018 May 2018. 5 $100,000 2018. Rent expense for the years ended December 31, 2018 2017 $228,000 $78,000, December 31, 2018 ( 2019 $ 259 2020 267 2021 274 2022 282 2023 94 Total $ 1,176 Employment Agreements We have entered into employment agreements with certain of our officers and employees which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon change in control of our Company, or by the employee for good reason. Litigation James L. Yeager, Ph.D., and Midwest Research Laboratories, LLC v. Innovus Pharmaceuticals, Inc. January 18, 2018, February 26, 2018 ( October 2018, Marin County District Attorney’s Letter August 24, 2018, ten November 2018, March 2019, In the ordinary course of business, the Company may third may, not Indemnities In addition to the indemnification provisions contained in our directors and officers. These agreements require the Company, among other things, to indemnify the directors or officers against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may not not no

Note 11 - Subsequent Events

Note 11 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 11 Reverse Stock Split On March 15, 2019, one 105 Private Placement On January 3, 2019, 431,490 $7.35 one one one $7.35 one one $8.40 not 9.99% 200,637 $0.105 32,362 7.5% $9.19 The Investor Warrants and Placement Agent Warrants are exercisable immediately upon issuance, subject to an issuance limitation set forth therein equal to the number of authorized and unreserved shares of Common Stock available for issuance on the date thereof, and shall terminate as follows: (i) the Series A Warrants shall terminate 18 five 4.99% may 9.99% 61 In connection with the sale of the Units, the Company granted certain registration rights with respect to the Shares and shares of Common Stock issuable upon exercise of the Investor Warrants, pursuant to a Registration Rights Agreement by and between us and the Investor (the “Registration Rights Agreement”). Under the terms of the Registration Rights Agreement, we agreed to file a registration statement no 30 January 14, 2019. Asset Purchase Agreement On January 1, 2019, $343,000 $313,000 $2.4 2018. Promissory Note In March 2019, third $400,000 0% $100,000 $500,000 12 18,000 We have evaluated subsequent events through the filing date of this Form 10 no

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Nature of Operations, Policy [Policy Text Block	Organization Innovus Pharmaceuticals, Inc., together with its subsidiaries is a Nevada formed, San Diego, California-based The Company’s business model leverages its ability to (a) develop and build its current pipeline of proprietary products, and (b) to also acquire outright or in-license commercial products that are supported by scientific and/or clinical evidence, place them through the Company’s existing supply chain, retail and on-line (including our Amazon®, eBay®, Wish.com, Walmart.com®, and Walgreens.com on-line stores and other e-commerce business platforms) channels to tap new markets and drive demand for such products and to establish physician relationships. The Company currently sells its products direct to consumer primarily in the United States and Canada and sells to international commercial partners in multiple countries around the world
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Principles of Consolidation These consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), and include all assets, liabilities, revenues and expenses of the Company and its wholly owned subsidiaries: FasTrack Pharmaceuticals, Inc. ("FasTrak"), Semprae Laboratories, Inc. (“Semprae”), Novalere, Inc. (“Novalere”), Supplement Hunt, Inc. (“Supplement Hunt”) and Prime Savings Club, Inc. (“Prime Savings Club”). All material intercompany transactions and balances have been eliminated. Certain items have been reclassified to conform to the current year presentation.
Reserve Stock Split, Policy [Policy Text Block]	Reverse Stock Split On March 15, 2019, ’ ’ one 105 not “ ”
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP ”
Liquidity, Policy [Policy Text Block]	Liquidity The Company’s operations have been financed primarily through proceeds from convertible debentures and notes payable, sales of its common stock and revenue generated from its products domestically and internationally through the Company's marketing platform and by its partners. These funds have provided Innovus with the resources to operate its business, sell and support its products, attract and retain key personnel and add new products to the Company's portfolio. The Company has experienced net losses and negative cash flows from operations each year since its inception. As of December 31, 2018, 43.9 2.3 In January 2019, $2.7 11 2018, 5.5 six $2.9 5, 7 11 As of December 31, 2018, 1.2 0.4 March 29, 2019, $1.7 $0.6 December 31, 2018, $6.1 first 2019 $2.7 11 12 June 30, 2016 $1.2 no may not
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurement The Company’s financial instruments are cash, accounts receivable, accounts payable, accrued liabilities, derivative liabilities, contingent consideration and debt. The recorded values of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The fair values of the warrant derivative liabilities and embedded conversion feature derivative liabilities are based upon the Black Scholes Option Pricing Model (“Black-Scholes”) and the Path-Dependent Monte Carlo Simulation Model calculations, respectively, and are a Level 3 8 3 3 The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 3 three ● Level 1 ● Level 2 1 ● Level 3
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Cash consists of cash held with financial institutions with original maturities of three may
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and accounts receivable. Accounts receivable consist primarily of cooperative marketing sales which are managed by a third third s products on e-commerce. The Company performs ongoing credit evaluations of its customers and generally do not Revenues consist primarily of product sales directly to end user customers. The Company has no 10% December 31, 2018 2017. December 31, 2018, 2017 two four 78% 72% The Company categorizes revenue by geographic area based on selling location. All operations are currently located in the U.S. The Company’s U.S. and Canada sales represented 80% 19%, December 31, 2018. none 10% The Company operates on the basis of a single reportable segment, which is the business of delivering over-the-counter medicines, consumer care products for men’s and women’s health and respiratory diseases, and other consumer care goods. The Company's chief operating decision-maker is the Chief Executive Officer, who evaluates us as a single operating segment.
Concentration Of Suppliers, Policy [Policy Text Block]	Concentration of Suppliers The Company has manufacturing relationships with a number of vendors or manufacturers for its various products. Pursuant to these relationships, the Company purchases products through purchase orders with its manufacturers.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market (net realizable value). Cost is determined on a first first The Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and raw materials on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment, including software, are recorded at historical cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets which range from three ten
Business Combinations Policy [Policy Text Block]	Business Combinations The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The final purchase price may one may not Unanticipated events and circumstances may may
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and Intangible Assets The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicates an impairment may two Step 1. may second no Step 2. Impairment may The goodwill was recorded as part of the acquisition of Semprae that occurred on December 24, 2013, February 5, 2015, March 1, 2016. no no December 31, 2018 2017. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives, which range from one fifteen
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not no December 31, 2018 2017, not
Debt, Policy [Policy Text Block]	Debt Issuance Costs Debt issuance costs represent costs incurred in connection with the notes payable and convertible debentures during the years ended December 31, 2018 2017.
Beneficial Conversion Features, Policy [Policy Text Block]	Beneficial Conversion Feature If a conversion feature of convertible debt is not
Derivatives, Policy [Policy Text Block]	Derivative Liabilities Prior to the adoption of ASU 2017 11, January 2015 not 815. 2017 11 January 1, 2018, no 8
Debt Extinguishment, Policy [Policy Text Block]	Debt Extinguishment Any gain or loss associated with debt extinguishment is recorded in the consolidated statements of operations in the period in which the debt is considered extinguished. Third party fees incurred in connection with a debt restructuring accounted for as an extinguishment are capitalized. Fees paid to third
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are provided for using the asset and liability method whereby deferred tax assets and liabilities are recognized using current tax rates on the difference between the financial statement carrying amounts and the respective tax basis of the assets and liabilities. The Company provides a valuation allowance on deferred tax assets when it is more likely than not not The Company recognizes the benefit of a tax position only after determining that the relevant tax authority would more likely than not 50% no December 31, 2018 2017 9
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition and Deferred Revenue The Company generates revenue from product sales and the licensing of the rights to market and commercialize our products. Revenue is measured based on consideration specified in a contract with a customer. A contract with a customer exists when the Company enters into an enforceable contract with a customer. The contract is based on either the acceptance of standard terms and conditions on the websites for e-commerce customers and via telephone with our third 30 A performance obligation is a promise in a contract to transfer a distinct product to the customer, which for the Company is transfer of over-the-counter drug and consumer care products to its customers. Performance obligations promised in a contract are identified based on the goods that will be transferred to the carrier who takes control of the product that are both capable of being distinct and are distinct in the context of the contract, whereby the transfer of the goods is separately identifiable from other promises in the contract. The transaction price of a contract is allocated to each distinct performance obligation and recognized as revenue when or as the customer receives the benefit of the performance obligation. The transaction price is determined based on the consideration to which we will be entitled to receive in exchange for transferring goods to the customer. We issue refunds to e-commerce and print media customers, upon request, within 30 90 not $194,000 $53,000 December 31, 2018 December 31, 2017, The Company recognizes revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer when product is shipped. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of product sales. The Company enters into exclusive distributor and license agreements that are within the scope of ASC Topic 606. three 1 2 3 no
Cost of Sales, Policy [Policy Text Block]	Cost of Product Sales Cost of product sales includes the cost of inventories, shipping costs, warehouse labor costs, royalties and inventory reserves. The Company is required to make royalty payments based upon the net sales of three October 2017, 2018
Advertising Costs, Policy [Policy Text Block]	Advertising Expense Advertising costs, which primarily includes print and online media advertisements, are expensed as incurred and are included in sales and marketing expense in the accompanying consolidated statements of operations. Advertising costs were approximately $14.1 $5.4 December 31, 2018 2017,
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development (“R&D”) costs, including research performed under contract by third
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with FASB ASC 718, Stock Based Compensation 718 No. 2016 09 January 1, 2017, Except for transactions with employees and directors that are within the scope of FASB ASC 718,
Equity Instruments, Issued To Nonemployees For Services, Policy [Policy Text Block]	Equity Instruments Issued to Non-Employees for Services The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows FASB guidance. As such, the value of the applicable stock-based compensation is periodically remeasured, and income or expense is recognized during the vesting terms of the equity instruments. The measurement date for the estimated fair value of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the estimated fair value of the equity instrument is primarily recognized over the term of the consulting agreement. According to FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable equity instruments should not
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding and vested but deferred RSUs during the period presented. Diluted net loss per share is computed using the weighted average number of common shares outstanding and vested but deferred RSUs during the periods plus the effect of dilutive securities outstanding during the periods. For the years ended December 31, 2018 2017, 7
Change in Accounting Principle, Policy [Policy Text Block]	Change in Accounting Principle On January 1, 2018, No. 2017 11, Earnings Per Share (Topic 260 480 815 no no January 1, 2018. January 1, 2018 $59,000 January 1, 2018. not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, No. 2016 02, Leases (Topic 842 606, Revenue from Contracts with Customers no 2016 02 December 15, 2018, not may not 2016 02 first 2019 December 31, 2018. December 31, 2018 We elected the standard's package of practical expedients on adoption, which allows us to carry forward our historical assessment of whether existing agreements contain a lease and the classification of our existing lease agreements as either operating or capital (referred to as operating or financing leases in the new standard). We did not not may While the Company is currently assessing the impact ASU 2016 02 10. In January 2017, 2017 04, Intangibles - Goodwill and Other (Topic 350 2 2 December 15, 2019, not In June 2018, 2018 07 December 15, 2018, not In August 2018, 2018 13 3 1 2. December 15, 2019, not In August 2018, 2018 15, Customer s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract December 31, 2020 In November 2018, 2018 18, Clarifying the Interaction Between Topic 808 606 606. December 31, 2020

Note 4 - Assets and Liabiliti_2

Note 4 - Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2018 2017 Raw materials and supplies $ 238 $ 165 Work in process 96 153 Finished goods 2,036 1,408 Total $ 2,370 $ 1,726
Property, Plant and Equipment [Table Text Block]	December 31, 2018 2017 Computer equipment $ 45 $ 22 Office furniture and fixtures 82 34 Leasehold improvements 186 25 Production equipment 285 278 Software 339 339 Total cost 937 698 Less accumulated depreciation (690 ) (636 ) Property and equipment, net $ 247 $ 62
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 31, 2018 Accumulated Useful Lives Amount Amortization Net Amount (years) Patent & Trademarks $ 654 $ (161 ) $ 493 7 - 15 Customer Contracts 625 (311 ) 314 10 Sensum+® License (from CRI) 234 (131 ) 103 10 Vesele® Trademark 25 (12 ) 13 8 Beyond Human® Website and Trade Name 222 (112 ) 110 5 - 10 Novalere Manufacturing Contract 4,681 (1,824 ) 2,857 10 Other Beyond Human® Intangible Assets 5 (5 ) - 1 - 3 Total $ 6,446 $ (2,556 ) $ 3,890 December 31, 2017 Accumulated Useful Lives Amount Amortization Net Amount (years) Patent & Trademarks $ 418 $ (125 ) $ 293 7 - 15 Customer Contracts 611 (250 ) 361 10 Sensum+® License (from CRI) 234 (107 ) 127 10 Vesele® Trademark 25 (10 ) 15 8 Beyond Human® Website and Trade Name 222 (72 ) 150 5 - 10 Novalere Manufacturing Contract 4,681 (1,356 ) 3,325 10 Other Beyond Human® Intangible Assets 5 (3 ) 2 1 - 3 Total $ 6,196 $ (1,923 ) $ 4,273
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2019 $ 706 2020 699 2021 657 2022 614 2023 578 Thereafter 636 Total $ 3,890
Schedule of Other Current Assets [Table Text Block]	December 31, 2018 2017 Prepaid insurance $ 173 $ 110 Prepaid inventory 251 125 Merchant net settlement reserve receivable 445 - Prepaid consulting and other expense 111 83 Prepaid CRI royalties 45 45 Other receivables 91 - Total $ 1,116 $ 363
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	December 31, 2018 2017 Accounts payable $ 1,845 $ 2,306 Accrued credit card balances 215 73 Accrued royalties 25 132 Sales returns and allowances 194 53 Accrual for stock to be issued to consultants 131 43 Accrued other 212 - Total $ 2,622 $ 2,607

Note 5 - Notes Payable and De_2

Note 5 - Notes Payable and Debentures - Non-related Parties (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	2018 2017 Notes payable: February 2016 Note Payable $ - $ 55 September 2017 5% Notes Payable - 165 October and December 2017 Notes Payable - 1,066 December 2017 5% Note Payable - 390 January and March 2018 Notes Payable 112 - February and March 5% Notes Payable 250 - July 2018 5% Notes Payable 550 - August 2018 Notes Payable 800 - September 2018 5% Notes Payable 390 - October 2018 5% Notes Payable 550 - November and December 2018 Notes Payable 1,429 - Total notes payable 4,081 1,676 Less: Debt discount (1,008 ) (437 ) Carrying value 3,073 1,239 Less: Current portion (3,073 ) (1,239 ) Notes payable, net of current portion $ - $ -
Schedule of Maturities of Long-term Debt [Table Text Block]	2019 $ 4,081

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2018 2017 Expected life (in years) 7.0 9.1 Expected volatility 188.8 % 213.6 % Average risk-free interest rate 2.67 % 2.30 % Dividend yield 0 % 0 % Grant date fair value $ 14.70 $ 15.75
Share-based Compensation, Stock Options, Activity [Table Text Block]	Options Weighted average exercise price Weighted remaining contractual life (years) Aggregate intrinsic value Outstanding at December 31, 2016 2,274 $ 22.67 8.6 $ 14,293 Granted 444 $ 16.19 - - Exercised (684 ) 7.17 - - Cancelled (1,184 ) $ 32.64 - - Forfeited - - - - Outstanding at December 31, 2017 850 $ 17.86 9.0 377 Granted 3,936 13.95 - - Exercised - - - - Cancelled (288 ) 14.93 - - Forfeited - - - - Outstanding at December 31, 2018 4,498 $ 14.63 9.2 $ 190 Vested and Expected to Vest at December 31, 2018 4,498 $ 14.63 9.2 $ 190 Vested and Expected to Vest at December 31, 2017 850 $ 17.86 9.0 $ 377
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	Restricted Stock Units Outstanding at December 31, 2016 122,644 Granted 27,709 Exchanged (877 ) Cancelled (23,810 ) Outstanding at December 31, 2017 125,666 Granted 71,528 Exchanged (6,797 ) Cancelled (14,632 ) Outstanding at December 31, 2018 175,765 Vested at December 31, 2018 107,817 Vested at December 31, 2017 94,044
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of December 31, 2018 2017 Gross number of shares excluded: Restricted stock units – unvested 67,948 31,622 Stock options 4,498 850 Warrants 319,493 566,195 Total 391,939 598,667
Warrant [Member]
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	2017 Expected life (in years) 5.0 Expected volatility 183.8 % Average risk-free interest rate 2.69 % Dividend yield 0 %

Note 8 - Derivative Liabiliti_2

Note 8 - Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Warrant derivative liabilities: Beginning balance December 31, 2016 $ 164 Change in fair value (105) Ending balance December 31, 2017 59 Cumulative adjustment from liabilities to accumulated deficit for the fair value of the warrant derivative liability upon adoption of ASU 2017-11 on January 1, 2018 (59) Change in fair value - Ending balance December 31, 2018 $ -

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	2018 2017 Current: Federal $ - $ - State - 3 Total current - 3 Deferred: Federal 1,347 1,056 State 618 (614 ) Change in valuation allowance (1,965 ) (442 ) Total deferred - - Income tax provision $ - $ 3
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2018 2017 Net operating loss carry-forwards $ 8,358 $ 6,730 State taxes 1 1 Equity based instruments 370 324 Deferred compensation 741 813 Intangibles - - Derivative liabilities - - Other 316 191 Total deferred tax assets 9,786 8,059 Intangibles (604 ) (825 ) Derivative liabilities (6 ) (5 ) Warrants - (2 ) Debt discount - (16 ) Other - - Total deferred tax liabilities (610 ) (848 ) Less: valuation allowance (9,176 ) (7,211 ) Net deferred tax assets $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2018 2017 Expected federal tax 21.00 % 34.00 % State tax (net of federal benefit) - % (0.03 )% Contingent consideration - % 0.86 % Fair value of embedded conversion feature in excess of allocated debt proceeds - % - % Loss on extinguishment of debt (2.58 )% (3.52 )% Restricted stock units (0.39 )% (0.18 )% Stock options - % (0.21 )% Change in federal tax rate - % (45.59 )% Release of valuation allowance - % 45.59 % Other (0.67 )% (0.12 )% Valuation allowance (17.36 )% (30.85 )% Total - % (0.05 )%

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2019 $ 259 2020 267 2021 274 2022 282 2023 94 Total $ 1,176

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)	Mar. 15, 2019	Jan. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Mar. 19, 2019USD ($)	Jan. 01, 2018USD ($)	Dec. 31, 2016USD ($)	Jun. 30, 2016USD ($)
Retained Earnings (Accumulated Deficit), Ending Balance				$ (43,860,000)	$ (35,640,000)
Working Capital Deficit				2,300,000
Proceeds from Notes Payable, Total				5,470,000	1,650,000
Proceeds from Stock Options and Warrant Exercises				2,900,000
Cash, Ending Balance				1,248,000	1,565,000			$ 830,000
Cash Held by Merchant Processors				400,000
Net Cash Provided by (Used in) Operating Activities, Total				(6,121,000)	(2,361,000)
Deferred Compensation Arrangement with Individual, Recorded Liability									$ 1,200,000
Goodwill, Impairment Loss				0	0
Impairment of Long-Lived Assets to be Disposed of				0	0
Unrecognized Tax Benefits, Ending Balance				0	0
Estimated Reserve for Sales Returns and Allowances				194,000	53,000
Advertising Expense				$ 14,100,000	$ 5,400,000
Minimum [Member]
Property, Plant and Equipment, Useful Life				3 years
Finite-Lived Intangible Asset, Useful Life				1 year
Maximum [Member]
Property, Plant and Equipment, Useful Life				10 years
Finite-Lived Intangible Asset, Useful Life				15 years
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Major Customers				2	4
Concentration Risk, Percentage				78.00%	72.00%
Sales Revenue, Net [Member] | UNITED STATES
Concentration Risk, Percentage				80.00%
Sales Revenue, Net [Member] | CANADA
Concentration Risk, Percentage				19.00%
Subsequent Event [Member]
Proceeds from Warrant Exercises		$ 2,700,000
Cash, Ending Balance						$ 1,700,000
Cash Held by Merchant Processors						$ 600,000
Proceeds from Issuance Initial Public Offering			$ 2,700,000
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	105
Retained Earnings [Member] | Accounting Standards Update 2017-11 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption							$ 59,000

Note 2 - License Agreements (De

Note 2 - License Agreements (Details Textual)

Oct. 19, 2018USD ($)

Jan. 18, 2018

Jan. 05, 2018

May 16, 2017

Nov. 09, 2016

Sep. 18, 2014USD ($)

Dec. 31, 2019

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Dec. 31, 2017CAD ($)

Mar. 31, 2018USD ($)

Dec. 31, 2018CAD ($)

Contract with Customer, Liability, Current

$ 108,000

$ 25,000

Products Related to the Acerus Pharmaceuticals Corporation Agreement [Member]

Revenue from Contract with Customer, Including Assessed Tax

311,000

Products Related to the Acerus Pharmaceuticals Corporation Agreement [Member] | Scenario, Forecast [Member]

Number of Units Obligated to Purchase

35,000

Product Related to Orimed Pharma Agreement [Member]

Contract with Customer, Liability, Milestone Method Revenue Recognized

0

Acerus [Member]

Finite-Lived Intangible Asset, Useful Life

10 years

License Agreement, Potential Milestone Payments

1,210,000

$ 1,650,000

Proceeds from License Fees Received

78,000

$ 100,000

Contract with Customer, Liability, Current

70,000

Contract with Customer, Liability, Revenue Recognized

509,000

Lavasta [Member]

Finite-Lived Intangible Asset, Useful Life

10 years

Proceeds from License Fees Received

$ 15,000

25,000

Contract with Customer, Liability, Current

23,000

Contract with Customer, Liability, Revenue Recognized

156,000

License Agreement Term

10 years

Luminarie Pty Ltd Agreement [Member]

Contract with Customer, Liability, Revenue Recognized

0

0

License Agreement Term

10 years

Densmore Pharmaceutical International Agreement [Member]

Proceeds from License Fees Received

8,000

Contract with Customer, Liability, Revenue Recognized

0

100,000

License Agreement Term

10 years

J&H [Member]

Contract with Customer, Liability, Revenue Recognized

82,000

60,000

License Agreement Term

10 years

License Agreement, Minimum Annual Order to Be Received for Product to Market and Sell

$ 2,000,000

Sothema [Member]

Proceeds from License Fees Received

200,000

Contract with Customer, Liability, Total

0

0

Contract with Customer, Liability, Milestone Method Revenue Recognized

0

0

Orimed [Member]

Proceeds from License Fees Received

$ 100,000

License Agreement Term

20 years

Contract with Customer, Liability, Total

98,000

31,000

Royalty Expense

$ 13,000

$ 4,000

Note 3 - Business and Asset A_2

Note 3 - Business and Asset Acquisitions (Details Textual) - USD ($)	Dec. 14, 2018	Feb. 01, 2017	Nov. 12, 2016	Feb. 05, 2015	Dec. 31, 2018	Dec. 31, 2017	Mar. 15, 2017
Inventory, Net, Total					$ 2,370,000	$ 1,726,000
Fair Value Adjustment for Contingent Consideration					$ 204,000	$ 194,000
Acquisition of Supplement Hunt [Member]
Payments to Acquire Businesses, Gross	$ 221,000
Inventory, Net, Total	96,000
Intangible Assets, Net (Including Goodwill), Total	$ 125,000
Acquisition of Novalere [Member]
Percentage of Closing Consideration Shares				50.00%
Percentage of ANDA Consideration Shares				50.00%
Net Revenue for Which Earn-out Payments Will Be Made				$ 5,000,000
Earn-out Payment to Be Made to Stockholders for Specified Level of Net Revenue				500,000
Cumulative Maximum Earn-out Payments				$ 2,500,000
Stock Issued During Period, Shares, Acquisitions		243,978	121,989
Percentage of Common Stock Shares, Registered			10.00%
Stock Issued During Period, Value, Acquisitions Contingent Consideration		$ 3,000,000
Number of Consideration Shares		1,323			1,323	1,323	1,323
Fair Value of Consideration Shares					$ 7	$ 9,000
Change in Estimated Fair Value of Future Earn-out Payments					0	0
Estimated Fair Value of Future Earn-out Payments					1,200,000
Acquisition of Novalere [Member] | Fair Value Adjustment for Contingent Consideration [Member]
Fair Value Adjustment for Contingent Consideration					$ (2,000)	$ (23,000)

Note 4 - Assets and Liabiliti_3

Note 4 - Assets and Liabilities (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Depreciation, Total	$ 54,000	$ 12,000
Amortization of Intangible Assets, Total	$ 634,000	$ 630,000

Note 4 - Assets and Liabiliti_4

Note 4 - Assets and Liabilities - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Raw materials and supplies	$ 238	$ 165
Work in process	96	153
Finished goods	2,036	1,408
Total	$ 2,370	$ 1,726

Note 4 - Assets and Liabiliti_5

Note 4 - Assets and Liabilities - Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property, plant and equipment, gross	$ 937	$ 698
Less accumulated depreciation	(690)	(636)
Property and equipment, net	247	62
Computer Equipment [Member]
Property, plant and equipment, gross	45	22
Furniture and Fixtures [Member]
Property, plant and equipment, gross	82	34
Leasehold Improvements [Member]
Property, plant and equipment, gross	186	25
Equipment [Member]
Property, plant and equipment, gross	285	278
Software [Member]
Property, plant and equipment, gross	$ 339	$ 339

Note 4 - Assets and Liabiliti_6

Note 4 - Assets and Liabilities - Amortizable Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Intangible Assets, Amount	$ 6,446	$ 6,196
Intangible Assets, Accumulated Amortization	(2,556)	(1,923)
Intangible Assets, Net Amount	$ 3,890	4,273
Minimum [Member]
Intangible Assets, Useful Lives (Year)	1 year
Maximum [Member]
Intangible Assets, Useful Lives (Year)	15 years
Patents and Trademarks [Member]
Intangible Assets, Amount	$ 654	418
Intangible Assets, Accumulated Amortization	(161)	(125)
Intangible Assets, Net Amount	$ 493	$ 293
Patents and Trademarks [Member] | Minimum [Member]
Intangible Assets, Useful Lives (Year)	7 years	7 years
Patents and Trademarks [Member] | Maximum [Member]
Intangible Assets, Useful Lives (Year)	15 years	15 years
Customer Contracts [Member]
Intangible Assets, Amount	$ 625	$ 611
Intangible Assets, Accumulated Amortization	(311)	(250)
Intangible Assets, Net Amount	$ 314	$ 361
Intangible Assets, Useful Lives (Year)	10 years	10 years
Sensum License [Member]
Intangible Assets, Amount	$ 234	$ 234
Intangible Assets, Accumulated Amortization	(131)	(107)
Intangible Assets, Net Amount	$ 103	$ 127
Intangible Assets, Useful Lives (Year)	10 years	10 years
Vesele [Member]
Intangible Assets, Amount	$ 25	$ 25
Intangible Assets, Accumulated Amortization	(12)	(10)
Intangible Assets, Net Amount	$ 13	$ 15
Intangible Assets, Useful Lives (Year)	8 years	8 years
Beyond Human Website and Trade Name [Member]
Intangible Assets, Amount	$ 222	$ 222
Intangible Assets, Accumulated Amortization	(112)	(72)
Intangible Assets, Net Amount	$ 110	$ 150
Beyond Human Website and Trade Name [Member] | Minimum [Member]
Intangible Assets, Useful Lives (Year)	5 years	5 years
Beyond Human Website and Trade Name [Member] | Maximum [Member]
Intangible Assets, Useful Lives (Year)	10 years	10 years
Novalere Mfg. Contract [Member]
Intangible Assets, Amount	$ 4,681	$ 4,681
Intangible Assets, Accumulated Amortization	(1,824)	(1,356)
Intangible Assets, Net Amount	$ 2,857	$ 3,325
Intangible Assets, Useful Lives (Year)	10 years	10 years
Other Beyond Human Intangible Assets [Member]
Intangible Assets, Amount	$ 5	$ 5
Intangible Assets, Accumulated Amortization	(5)	(3)
Intangible Assets, Net Amount		$ 2
Other Beyond Human Intangible Assets [Member] | Minimum [Member]
Intangible Assets, Useful Lives (Year)	1 year	1 year
Other Beyond Human Intangible Assets [Member] | Maximum [Member]
Intangible Assets, Useful Lives (Year)	3 years	3 years

Note 4 - Assets and Liabiliti_7

Note 4 - Assets and Liabilities - Expected Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
2019	$ 706
2020	699
2021	657
2022	614
2023	578
Thereafter	636
Total	$ 3,890	$ 4,273

Note 4 - Assets and Liabiliti_8

Note 4 - Assets and Liabilities - Prepaid Expense and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Prepaid insurance	$ 173	$ 110
Prepaid inventory	251	125
Merchant net settlement reserve receivable	445
Prepaid consulting and other expense	111	83
Prepaid CRI royalties	45	45
Other receivables	91
Total	$ 1,116	$ 363

Note 4 - Assets and Liabiliti_9

Note 4 - Assets and Liabilities - Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounts payable	$ 1,845	$ 2,306
Accrued credit card balances	215	73
Accrued royalties	25	132
Sales returns and allowances	194	53
Accrual for stock to be issued to consultants	131	43
Accrued other	212
Total	$ 2,622	$ 2,607

Note 5 - Notes Payable and De_3

Note 5 - Notes Payable and Debentures - Non-related Parties (Details Textual)	Dec. 15, 2018USD ($)	Nov. 30, 2018USD ($)shares	Nov. 06, 2018USD ($)shares	Oct. 22, 2018USD ($)shares	Oct. 08, 2018USD ($)shares	Sep. 15, 2018USD ($)	Sep. 12, 2018USD ($)shares	Aug. 01, 2018USD ($)shares	Jul. 31, 2018USD ($)shares	Jul. 23, 2018USD ($)shares	Jul. 19, 2018USD ($)shares	Jun. 15, 2018USD ($)	Mar. 01, 2018USD ($)shares	Feb. 24, 2018USD ($)	Dec. 13, 2017USD ($)	Sep. 20, 2017USD ($)shares	Feb. 24, 2016USD ($)	Apr. 30, 2018USD ($)shares	Mar. 31, 2018USD ($)shares	Feb. 28, 2018USD ($)	Jan. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Oct. 31, 2017USD ($)	Dec. 31, 2018USD ($)shares	Mar. 31, 2018USD ($)shares	Mar. 31, 2018USD ($)shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)shares
Debt Instrument, Unamortized Discount, Total																						$ 437,000		$ 1,008,000			$ 1,008,000	$ 437,000
Gain (Loss) on Extinguishment of Debt, Total																											$ (1,332,000)	$ (700,000)
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares																											90,644	26,905
Stock Issued During Period, Value, Restricted Stock Award, Gross
Interest Expense, Debt, Total																											55,000	73,000
Amortization of Debt Discount (Premium) to Interest Expense																											1,400,000	$ 348,000
Third-party Consultant [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares																								8,193
Stock Issued During Period, Value, Restricted Stock Award, Gross																								$ 88,000
Short Term Loan With Certain Merchant Processors [Member]
Short-term Debt, Total																								157,000			157,000
Short-term Loan Payable [Member]
Proceeds from Insurance Premiums Collected																											175,000
Debt Instrument, Nine Monthly Installment Payment																											16,000
Debt Instrument, Six Monthly Installment Payment																											6,000
Short-term Debt, Total																								$ 108,000			$ 108,000
February 2016 Note Payable [Member] | SBI [Member]
Proceeds from Issuance of Debt																	$ 550,000
Debt Instrument, Interest Rate, Stated Percentage																	20.00%
Debt Instrument, Term																	2 years
Debt Instrument, Periodic Payment, Total														$ 28,000
September 2017 Note Payable [Member]
Proceeds from Issuance of Debt																$ 150,000
Debt Instrument, Interest Rate, Stated Percentage																5.00%						5.00%		5.00%			5.00%	5.00%
Debt Instrument, Original Issue Discount																$ 15,000
Debt Instrument, Face Amount																$ 165,000
Stock Issued During Period, Shares, Debt Instrument Issuance | shares																8,524
Debt Instrument, Unamortized Discount, Total																$ 70,000
September 2017 Note Payable [Member] | Fair Value in Excess of the Settled Principal and Interest Balance [Member]
Gain (Loss) on Extinguishment of Debt, Total																		$ 27,000
September 2017 Note Payable [Member] | Unamortized Debt Discount [Member]
Gain (Loss) on Extinguishment of Debt, Total																		$ 12,000
September 2017 Note Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares																		14,041
Debt Conversion, Original Debt, Amount																		$ 170,000
Debt Conversion, Converted Instrument, Amount																		196,000
October and December 2017 Notes Payable [Member]
Proceeds from Issuance of Debt																						$ 500,000	$ 500,000
Debt Instrument, Interest Rate, Stated Percentage																						0.00%						0.00%
Debt Instrument, Original Issue Discount																						$ 200,000						$ 200,000
October and December 2017 Notes Payable [Member] | Fair Value in Excess of the Settled Principal and Interest Balance [Member]
Gain (Loss) on Extinguishment of Debt, Total									$ 117,000				$ 218,000
October and December 2017 Notes Payable [Member] | Unamortized Debt Discount [Member]
Gain (Loss) on Extinguishment of Debt, Total									$ 67,000				38,000
October and December 2017 Notes Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares									22,676
Debt Conversion, Original Debt, Amount									$ 250,000				167,000
Debt Conversion, Converted Instrument, Amount									$ 367,000				$ 385,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares													21,429
October 2017 Notes Payable [Member]
Debt Instrument, Number of Payments																							9
Debt Instrument, Periodic Payment, Interest																						$ 50,000	$ 67,000
Debt Instrument, Interest Rate, Effective Percentage																							27.00%
December 2017 Note Payable [Member]
Proceeds from Issuance of Debt															$ 350,000
Debt Instrument, Interest Rate, Stated Percentage															5.00%							5.00%						5.00%
Debt Instrument, Periodic Payment, Total	$ 132,000					$ 133,000						$ 140,000
Debt Instrument, Original Issue Discount															$ 40,000
Debt Conversion, Converted Instrument, Shares Issued | shares										36,502
Debt Instrument, Number of Payments																						12						12
Debt Instrument, Interest Rate, Effective Percentage																						20.00%						20.00%
December 2017 Note Payable [Member] | Fair Value in Excess of the Settled Principal and Interest Balance [Member]
Gain (Loss) on Extinguishment of Debt, Total										$ 280,000
December 2017 Note Payable [Member] | Unamortized Debt Discount [Member]
Gain (Loss) on Extinguishment of Debt, Total										43,000
December 2017 Note Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Conversion, Original Debt, Amount										402,000
Debt Conversion, Converted Instrument, Amount										$ 682,000
January and March 2018 Notes Payable [Member]
Proceeds from Issuance of Debt																			$ 550,000		$ 678,000
Debt Instrument, Interest Rate, Stated Percentage																			0.00%						0.00%	0.00%
Debt Instrument, Original Issue Discount																			$ 269,000						$ 269,000	$ 269,000
Debt Instrument, Face Amount																			1,500,000						1,500,000	1,500,000
Debt Instrument, Unamortized Discount, Total																			$ 188,000		227,000				$ 188,000	$ 188,000
Debt Instrument, Number of Payments																			12						12	12
Debt Instrument, Interest Rate, Effective Percentage																			22.00%						22.00%	22.00%
Debt Instrument, Periodic Payment, Principal																		$ 56,000		$ 68,000
January and March 2018 Notes Payable [Member] | Three Unrelated Third-party Investors [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares																										12,210
January and March 2018 Notes Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares			11,905						27,211
Debt Conversion, Original Debt, Amount			$ 100,000						$ 300,000
Debt Conversion, Converted Instrument, Amount			133,000						440,000
January and March 2018 Notes Payable [Member] | Fair Value in Excess of the Settled Principal and Interest Balance [Member]
Gain (Loss) on Extinguishment of Debt, Total			33,000						140,000
January and March 2018 Notes Payable [Member] | Unamortized Debt Discount [Member]
Gain (Loss) on Extinguishment of Debt, Total			$ 24,000						$ 100,000
January 2018 Notes Payable [Member] | Third-party Consultant [Member]
Stock Issued During Period, Value, Restricted Stock Award, Gross																					5,918
March 2018 Notes Payable [Member] | Third-party Consultant [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares																			2,998
Stock Issued During Period, Value, Restricted Stock Award, Gross																			$ 55,000		$ 68,000
February and March 2018 Notes Payable [Member]
Proceeds from Issuance of Debt																										$ 650,000
Debt Instrument, Interest Rate, Stated Percentage																			5.00%			5.00%			5.00%	5.00%		5.00%
Debt Instrument, Original Issue Discount																			$ 70,000						$ 70,000	$ 70,000
Debt Instrument, Face Amount																			720,000						720,000	720,000
Debt Instrument, Unamortized Discount, Total																			$ 129,000						$ 129,000	$ 129,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares																									14,143
February and March 2018 Notes Payable [Member] | Fair Value in Excess of the Settled Principal and Interest Balance [Member]
Gain (Loss) on Extinguishment of Debt, Total		$ (88,000)			$ 145,000
February and March 2018 Notes Payable [Member] | Unamortized Debt Discount [Member]
Gain (Loss) on Extinguishment of Debt, Total					$ (3,000)
February and March 2018 Notes Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares		20,940			40,481
Debt Conversion, Original Debt, Amount		$ 143,000			$ 340,000
Debt Conversion, Converted Instrument, Amount		231,000			$ 485,000
Second March 2018 Note Payable [Member]
Debt Instrument, Number of Payments																			3						3	3
February 2018 Note Payable [Member]
Debt Instrument, Unamortized Discount, Total																				$ 94,000
July 2018 Notes Payable [Member]
Proceeds from Issuance of Debt											$ 500,000
Debt Instrument, Interest Rate, Stated Percentage											5.00%											5.00%						5.00%
Debt Instrument, Original Issue Discount											$ 50,000
Debt Instrument, Face Amount											550,000
Debt Instrument, Unamortized Discount, Total											$ 226,000
July 2018 Notes Payable [Member] | Three Unrelated Third-party Investors [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares											15,239
August 2018 Notes Payable [Member]
Proceeds from Issuance of Debt								$ 1,000,000
Debt Instrument, Interest Rate, Stated Percentage								0.00%
Debt Instrument, Original Issue Discount								$ 200,000
Debt Instrument, Unamortized Discount, Total								$ 435,000
Debt Instrument, Number of Payments								12
Debt Instrument, Interest Rate, Effective Percentage								20.00%
Debt Instrument, Periodic Payment, Principal								$ 100,000
August 2018 Notes Payable [Member] | Third-party Consultant [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares								6,086
Stock Issued During Period, Value, Restricted Stock Award, Gross								$ 100,000
August 2018 Notes Payable [Member] | Investors [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares								9,524
September 2018 Notes Payable [Member]
Proceeds from Issuance of Debt							$ 350,000
Debt Instrument, Interest Rate, Stated Percentage							5.00%															5.00%						5.00%
Debt Instrument, Original Issue Discount							$ 40,000
Debt Instrument, Face Amount							$ 390,000
Debt Instrument, Number of Payments							3
September 2018 Notes Payable [Member] | Unrelated Third Party Investor [Member]
Proceeds from Issuance of Debt				$ 500,000
Debt Instrument, Unamortized Discount, Total							$ 130,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares							9,524
October 2018 Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage				5.00%																		5.00%						5.00%
Debt Instrument, Original Issue Discount				$ 50,000
Debt Instrument, Face Amount				550,000
Debt Instrument, Unamortized Discount, Total				$ 176,000
October 2018 Notes Payable [Member] | Three Unrelated Third-party Investors [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares				15,239
November and December 2018 Notes Payable [Member]
Proceeds from Issuance of Debt																								$ 1,250,000
Debt Instrument, Interest Rate, Stated Percentage																								0.00%			0.00%
Debt Instrument, Original Issue Discount																								$ 270,000			$ 270,000
Debt Instrument, Face Amount																								1,520,000			1,520,000
November and December 2018 Notes Payable [Member] | Three Unrelated Third-party Investors [Member]
Debt Instrument, Unamortized Discount, Total		$ 374,000																						$ 125,000			$ 125,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares																								14,763

Note 5 - Notes Payable and De_4

Note 5 - Notes Payable and Debentures - Non-related Parties - Summary of Outstanding Notes Payable (Details) - USD ($)	Dec. 31, 2018	Oct. 22, 2018	Aug. 01, 2018	Jul. 19, 2018	Mar. 31, 2018	Jan. 31, 2018	Dec. 31, 2017	Sep. 20, 2017
Notes payable	$ 4,081,000						$ 1,676,000
Less: Debt discount	(1,008,000)						(437,000)
Carrying value	3,073,000						1,239,000
Less: Current portion	(3,073,000)						(1,239,000)
Notes payable, net of current portion
February 2016 Note Payable [Member]
Notes payable							55,000
September 2017 Note Payable [Member]
Notes payable							165,000
Less: Debt discount								$ (70,000)
October and December 2017 Notes Payable [Member]
Notes payable							1,066,000
December 2017 Note Payable [Member]
Notes payable							390,000
January and March 2018 Notes Payable [Member]
Notes payable	112,000
Less: Debt discount					$ (188,000)	$ (227,000)
February and March 2018 Notes Payable [Member]
Notes payable	250,000
Less: Debt discount					$ (129,000)
July 2018 Notes Payable [Member]
Notes payable	550,000
Less: Debt discount				$ (226,000)
August 2018 Notes Payable [Member]
Notes payable	800,000
Less: Debt discount			$ (435,000)
September 2018 Notes Payable [Member]
Notes payable	390,000
October 2018 Notes Payable [Member]
Notes payable	550,000
Less: Debt discount		$ (176,000)
November and December 2018 Notes Payable [Member]
Notes payable	$ 1,429,000

Note 5 - Notes Payable and De_5

Note 5 - Notes Payable and Debentures - Non-related Parties - Summary of Outstanding Notes Payable (Details) (Parentheticals)	Dec. 31, 2018	Oct. 22, 2018	Sep. 12, 2018	Jul. 19, 2018	Mar. 31, 2018	Dec. 31, 2017	Dec. 13, 2017	Sep. 20, 2017
September 2017 Note Payable [Member]
Interest rate	5.00%					5.00%		5.00%
December 2017 Note Payable [Member]
Interest rate						5.00%	5.00%
February and March 2018 Notes Payable [Member]
Interest rate					5.00%	5.00%
July 2018 Notes Payable [Member]
Interest rate				5.00%		5.00%
September 2018 Notes Payable [Member]
Interest rate			5.00%			5.00%
October 2018 Notes Payable [Member]
Interest rate		5.00%				5.00%

Note 5 - Notes Payable and De_6

Note 5 - Notes Payable and Debentures - Non-related Parties - Future Minimum Payments for Notes Payable (Details) $ in Thousands	Dec. 31, 2018USD ($)
2019	$ 4,081

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual)	Oct. 10, 2017shares	Jun. 16, 2017USD ($)	Mar. 21, 2017USD ($)$ / sharesshares	Jan. 19, 2017shares	Dec. 16, 2016USD ($)shares	Nov. 17, 2016USD ($)	Sep. 01, 2016shares	Aug. 23, 2016shares	Jul. 16, 2016shares	Mar. 21, 2016shares	Feb. 28, 2013shares	Mar. 31, 2017$ / sharesshares	Jan. 31, 2017shares	Jul. 31, 2016USD ($)shares	Nov. 30, 2014shares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015$ / sharesshares	Mar. 31, 2018$ / sharesshares	Mar. 15, 2017shares	Feb. 01, 2017shares	Jan. 31, 2015$ / sharesshares
Common Stock, Shares Authorized																292,500,000	292,500,000	292,500,000
Common Stock, Par or Stated Value Per Share | $ / shares																$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized																7,500,000	7,500,000	7,500,000
Proceeds From Issuance Or Sale Of Equity, Gross | $			$ 3,850,000
Proceeds from Issuance or Sale of Equity, Total | $			$ 3,310,000															$ 3,308,000
Shares Issued, Price Per Share | $ / shares			$ 15.75
Warrants and Rights Outstanding, Term																	3 years 36 days
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																	$ 19.51				$ 19.69			$ 31.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																					12,223
Stock Issued During Period, Value, Issued for Services | $																	$ 23,000	$ 629,000
Stock Issued During Period, Shares, Issued for Services																	2,602	1,803
Stock Issued During Period, Shares, Restricted Stock Award, Gross																	90,644	26,905
Common Stock, Value, Issued, Ending Balance | $																$ 2,000	$ 2,000	$ 2,000
Stock Issued During Period, Value, Restricted Stock Award, Gross | $
Amortization of Debt Discount (Premium) | $																	$ 1,369,000	778,000
Relative Fair Value Of Common Stock, Value, Notes Payable | $																		$ 217,000
Class of Warrant or Right, Outstanding																	319,493							2,381
Warrants and Rights Outstanding | $																	$ 0
Weighted Average Number of Shares Outstanding, Basic and Diluted																	1,989,134	1,504,135
Acquisition of Novalere [Member]
Number of Consideration Shares																1,323	1,323	1,323				1,323	1,323
The 2013 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized											95,268
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period											3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period											10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant																	0
The 2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized															190,477
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period															3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant															86
The 2016 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										190,477
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period										3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period										10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant																	139,911
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Increased, Percentage of number of shares of common stock issued and outstanding										4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized												53,936
Conversion of Debt to Shares of Restricted Common Stock [Member]
Debt Conversion, Original Debt, Amount | $																	$ 1,872,000	$ 1,093,000
Debt Conversion, Converted Instrument, Shares Issued																	195,186	122,240
Restricted Stock [Member]
Amortization of Debt Discount (Premium) | $																	$ 1,241,000	$ 217,000
Relative Fair Value Of Common Stock, Value, Notes Payable | $																	$ 2,918,000	$ 1,324,000
Weighted Average Number of Shares Outstanding, Basic and Diluted																	103,823	100,436
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																	0.00%	0.00%
Allocated Share-based Compensation Expense, Total | $																		$ 13,000	$ 7,000
Weighted Average Number of Shares Outstanding, Basic and Diluted																	1,885,311	1,403,699
Restricted Stock Units (RSUs) [Member]
Allocated Share-based Compensation Expense, Total | $																	$ 457,000	$ 329,000
Settlement of Vested Restricted Stock Units from Date of Issuance, Period																		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted, Fair Value | $																	1,100,000	$ 516,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options | $																	$ 823,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																	2 years 36 days
General and Administrative Expense [Member]
Stock Issued During Period, Value, Issued for Services | $																	$ 23,000	19,000
Service Agreement In October 2017 [Member]
Stock Issuable During Period, Shares, Issuable for Services	19,048
Stock Issued During Period, Value, Issued for Services | $																		3,175
Service Agreement In October 2017 [Member] | General and Administrative Expense [Member]
Stock Issued During Period, Value, Issued for Services | $																		$ 29,000
Service Agreement in November 2016 [Member]
Stock Issued During Period, Value, Issued for Services | $						$ 2,620
Service Agreement in November 2016 [Member] | General and Administrative Expense [Member]
Stock Issued During Period, Value, Issued for Services | $						$ 52,000
Service Agreement in September 2016 [Member]
Stock Issuable During Period, Shares, Issuable for Services							19,048									11,429
Stock Issued During Period, Shares, Issued for Services																	0	14,186
Service Agreement in September 2016 [Member] | General and Administrative Expense [Member]
Stock Issued During Period, Value, Issued for Services | $																		$ 206,000
Consulting Agreement In August 2016 [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross								15,239										7,620
Common Stock, Number of Payments								4
Common Stock, Value, Issued, Ending Balance | $																$ 360,000		$ 360,000
Consulting Agreement In August 2016 [Member] | General and Administrative Expense [Member]
Stock Issued During Period, Value, Restricted Stock Award, Gross | $																		465,000
Service Agreement In July 2016 [Member]
Stock Issued During Period, Value, Issued for Services | $		$ 15,000			$ 15,000													28,000
Stock Issued During Period, Shares, Issued for Services				752	762				2,381
HCW [Member]
Reimbursement of Offering Cost | $			$ 443,000
Other Offering Cost, Offset Against Proceeds from Offering | $			99,000
CRI [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross													2,143	953
Stock Issued During Period, Value, Restricted Stock Award, Gross | $														$ 23,000			$ 45,000
Series A and Series B Warrants in Connection with Public Equity Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $			3,310,000
Common Stock [Member]
Proceeds from Issuance or Sale of Equity, Total | $			1,590,000
Stock Issued During Period, Value, Issued for Services | $
Stock Issued During Period, Shares, Issued for Services																	2,603,000	27,535
Stock Issued During Period, Shares, Restricted Stock Award, Gross																	6,797	877
Stock Issued During Period, Value, Restricted Stock Award, Gross | $
Relative Fair Value Of Common Stock, Value, Notes Payable | $
Series A Warrants in Connection with Public Equity Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $			1,080,000
Series B Warrants in Connection with Public Equity Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $			$ 640,000
Series A Warrants in Connection with Public Equity Offering [Member]
Warrants and Rights Outstanding, Term			5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 15.75									$ 15.75
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												244,445
Class of Warrant or Right, Exercised During Period																	953
Series B Warrants in Connection with Public Equity Offering [Member]
Warrants and Rights Outstanding, Term			1 year
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 15.75									$ 15.75									$ 19.69
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			244,445									244,445									8,219
Class of Warrant or Right, Exercised During Period																	180,247
Warrants in Connection with Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			244,445
Warrants in Connection with Public Offering [Member] | HCW [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 19.688
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			12,223
Percentage of Common Stock Sold in Public Offering			125.00%
Class of Warrant or Right, Issued During Period, Fair Value | $			$ 130,000
Warrants in Connection with Debenture in 2015 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																				$ 9.408
Class of Warrant or Right, Issued During Period																				5,588
Warrants In Connection With Quart Three 2015 Notes [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																				$ 31.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																	7,377		9,846	17,223
Warrants in Connection with Debenture in 2016 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																	$ 42
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																	40,201

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Stock Options, Valuation Assumptions (Details) - Stock Options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Expected life (in years) (Year)	7 years	9 years 36 days
Expected volatility	188.80%	213.60%
Average risk-free interest rate	2.67%	2.30%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Grant date fair value (in dollars per share)	$ 14.70	$ 15.75

Note 7 - Stockholders' Equity_3

Note 7 - Stockholders' Equity - Schedule of Stock Option Activity (Details) - Stock Options [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Outstanding, Options (in shares)	850	2,274
Outstanding, Weighted average exercise price (in dollars per share)	$ 17.86	$ 22.67
Outstanding, Weighted remaining contractual life (Year)	9 years 73 days	9 years	8 years 219 days
Outstanding, Aggregate intrinsic value	$ 190	$ 377	$ 14,293
Granted, Options (in shares)	3,936	444
Granted, Weighted average exercise price (in dollars per share)	$ 13.95	$ 16.19
Granted, Weighted remaining contractual life (Year)
Granted, Aggregate intrinsic value
Exercised, Options (in shares)		(684)
Exercised, Weighted average exercise price (in dollars per share)		$ 7.17
Cancelled, Options (in shares)	(288)	(1,184)
Cancelled, Weighted average exercise price (in dollars per share)	$ 14.93	$ 32.64
Forfeited, Options (in shares)
Forfeited, Weighted average exercise price (in dollars per share)
Outstanding, Options (in shares)	4,498	850	2,274
Outstanding, Weighted average exercise price (in dollars per share)	$ 14.63	$ 17.86	$ 22.67
Vested and Expected to Vest, Options (in shares)	4,498	850
Vested and Expected to Vest, Weighted average exercise price (in dollars per share)	$ 14.63	$ 17.86
Vested and Expected to Vest, Weighted remaining contractual life (Year)	9 years 73 days	9 years
Vested and Expected to Vest, Aggregate intrinsic value	$ 190	$ 377

Note 7 - Stockholders' Equity_4

Note 7 - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member] - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Outstanding (in shares)	125,666	122,644
Granted (in shares)	71,528	27,709
Exchanged (in shares)	(6,797)	(877)
Cancelled (in shares)	(14,632)	(23,810)
Outstanding (in shares)	175,765	125,666
Vested (in shares)	107,817	94,044

Note 7 - Stockholders' Equity_5

Note 7 - Stockholders' Equity - Warrants Valuation Assumptions (Details)	Dec. 31, 2018yr
Measurement Input, Expected Term [Member]
Black-Scholes measurement input for warrants (Year)	5
Measurement Input, Price Volatility [Member]
Black-Scholes measurement input for warrants (Year)	1.838
Measurement Input, Risk Free Interest Rate [Member]
Black-Scholes measurement input for warrants (Year)	0.0269
Measurement Input, Expected Dividend Rate [Member]
Black-Scholes measurement input for warrants (Year)	0

Note 7 - Stockholders' Equity_6

Note 7 - Stockholders' Equity - Schedule of Antidilutive Securities (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities (in shares)	391,939	598,667
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities (in shares)	67,948	31,622
Stock Options [Member]
Antidilutive Securities (in shares)	4,498	850
Warrant [Member]
Antidilutive Securities (in shares)	319,493	566,195

Note 8 - Derivative Liabiliti_3

Note 8 - Derivative Liabilities - Fair Value Measurement Using Level 3 Inputs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Warrant derivative liabilities, balance	$ 59	$ 164
Warrant derivative liabilities,Change in fair value		(105)
Cumulative adjustment from liabilities to accumulated deficit for the fair value of the warrant derivative liability upon adoption of ASU 2017-11 on January 1, 2018	(59)
Warrant derivative liabilities, balance		$ 59

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 24, 2013
Tax Credit Carryforward, Amount, Prior 2018	$ 24,400,000
Tax Credit Carryforward, Amount	$ 5,600,000
Offset Taxable Income, Percentage	80.00%
Deferred Tax Assets, Net, Total	$ 0	$ 0
Tax Cuts and Jobs Act of 2017 Provisional Adjustment of Deferred Tax Asset Liabilities		3,100,000
Deferred Tax Assets, Valuation Allowance, Total	9,176,000	7,211,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	2,000,000
Operating Loss Carryforwards, Per Year			$ 44,000
Operating Loss Carryforwards, Available to Use, Going Forward, Approximately			844,000
Unrecognized Tax Benefits, Ending Balance	0	0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	$ 0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	30,000,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	$ 29,300,000
Federal and California [Member]
Operating Loss Carryforwards, Total			$ 19,482,000

Note 9 - Income Taxes - Provisi

Note 9 - Income Taxes - Provisions for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Current:
Federal
State		3
Total current		3
Deferred:
Federal	1,347	1,056
State	618	(614)
Change in valuation allowance	(1,965)	(442)
Total deferred
Income tax provision		$ 3

Note 9 - Income Taxes - Deferre

Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Net operating loss carry-forwards	$ 8,358,000	$ 6,730,000
State taxes	1,000	1,000
Equity based instruments	370,000	324,000
Deferred compensation	741,000	813,000
Intangibles
Derivative liabilities
Other	316,000	191,000
Total deferred tax assets	9,786,000	8,059,000
Intangibles	(604,000)	(825,000)
Derivative liabilities	(6,000)	(5,000)
Warrants		(2,000)
Debt discount		(16,000)
Other
Total deferred tax liabilities	(610,000)	(848,000)
Less: valuation allowance	(9,176,000)	(7,211,000)
Net deferred tax assets	$ 0	$ 0

Note 9 - Income Taxes - Income

Note 9 - Income Taxes - Income Tax Reconciliation (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Expected federal tax	21.00%	34.00%
State tax (net of federal benefit)		(0.03%)
Contingent consideration		0.86%
Fair value of embedded conversion feature in excess of allocated debt proceeds
Loss on extinguishment of debt	(2.58%)	(3.52%)
Restricted stock units	(0.39%)	(0.18%)
Stock options		(0.21%)
Change in federal tax rate		(45.59%)
Release of valuation allowance		45.59%
Other	(0.67%)	(0.12%)
Valuation allowance	(17.36%)	(30.85%)
Total		(0.05%)

Note 10 - Commitments and Con_3

Note 10 - Commitments and Contingencies (Details Textual)	Feb. 01, 2017USD ($)shares	Nov. 12, 2016shares	Dec. 31, 2017USD ($)shares	Oct. 31, 2017ft²	May 31, 2017	Dec. 31, 2013USD ($)	Dec. 31, 2017USD ($)shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)shares	Mar. 15, 2017shares	Dec. 10, 2013ft²
Fair Value Adjustment for Contingent Consideration								$ 204,000	$ 194,000
Commercial Agreement, Initial Term					2 years
Commercial Agreement, Automatic Renewal Term					1 year
Operating Leases, Rent Expense, Total								228,000	78,000
Indemnities Liabilities								0
Lease Agreement for Office Space, San Diego, CA [Member]
Area of Real Estate Property | ft²											2,578
Operating Lease, Rent Expense, Monthly						$ 7,000
Base Rent, Increase (Decrease) Annually, Percent						4.00%
Lease Deposit Reimbursement on Termination of Lease			$ 15,000
Moving Expense, Reimbursement									$ 22,000
Commercial Lease Agreement for Office and Warehouse, San Diego, CA [Member]
Area of Real Estate Property | ft²				16,705
Base Rent, Increase (Decrease) Annually, Percent				3.00%
Operating Lease, Initial Rent Expense, Monthly							$ 21,000
Operating Lease, Term, Option to Extend				5 years
Allowance for Tenant Improvement								$ 100,000
Acquisition of Novalere [Member]
Stock Issued During Period, Shares, Acquisitions | shares	243,978	121,989
Percentage of Common Stock Shares, Registered		10.00%
Stock Issued During Period, Value, Acquisitions Contingent Consideration	$ 3,000,000
Number of Consideration Shares | shares	1,323		1,323				1,323	1,323	1,323	1,323
Fair Value of Consideration Shares			$ 9,000				$ 9,000	$ 7	$ 9,000
Acquisition of Novalere [Member] | Fair Value Adjustment for Contingent Consideration [Member]
Fair Value Adjustment for Contingent Consideration								$ (2,000)	$ (23,000)

Note 10 - Commitments and Con_4

Note 10 - Commitments and Contingencies - Operating Lease Future Minimum Payments (Details) $ in Thousands	Dec. 31, 2018USD ($)
2019	$ 259
2020	267
2021	274
2022	282
2023	94
Total	$ 1,176

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual)	Mar. 15, 2019	Jan. 03, 2019$ / sharesshares	Jan. 01, 2019USD ($)	Mar. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)shares	Mar. 31, 2018$ / sharesshares	Jan. 31, 2015$ / shares
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 19.51		$ 19.69	$ 31.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							12,223
Inventory, Net, Total | $					$ 2,370,000	$ 1,726,000
Proceeds from Notes Payable, Total | $					5,470,000	1,650,000
Debt Instrument, Unamortized Discount, Total | $					$ 1,008,000	$ 437,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross					90,644	26,905
Prime Consultants, LLC [Member]
Revenue from Contract with Customer, Including Assessed Tax | $					$ 2,400,000
Subsequent Event [Member]
Number of Common Stock, Per Unit		1
Beneficial Ownership, Percentage		9.99%
Percentage of Aggregate Shares		7.50%
Beneficial Ownership Limitation, Percentage		4.99%
Number of Warrant, Per Unit		1
Subsequent Event [Member] | Unrelated Third Party Investor [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross				18,000
Subsequent Event [Member] | Promissory Note [Member]
Proceeds from Notes Payable, Total | $				$ 400,000
Debt Instrument, Interest Rate, Stated Percentage				0.00%
Debt Instrument, Unamortized Discount, Total | $				$ 100,000
Debt Instrument, Periodic Payment, Total | $				$ 500,000
Debt Instrument, Term				1 year
Subsequent Event [Member] | Asset Purchase Agreement with Prime Consultants [Member]
Payments to Acquire Businesses, Gross | $			$ 343,000
Inventory, Net, Total | $			$ 313,000
Subsequent Event [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 7.35
Subsequent Event [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 8.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		32,362
Subsequent Event [Member] | Series C Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.105
Class of Warrant or Right, Exercised During Period		200,637
Subsequent Event [Member] | Warrant Issued Under Securities Purchased Agreement [Member]
Number of Equity Units Issued During period		431,490
Subsequent Event [Member] | Stock Issued Under Securities Purchased Agreement [Member]
Unit Price, Per Share | $ / shares		$ 7.35
Subsequent Event [Member] | Private Placement [Member] | Series C Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 9.19
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	105